Lipocine Inc
NASDAQ:LPCN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shenzhen SDG Service Co Ltd
SZSE:300917
|
CN |
|
C
|
Cowell e Holdings Inc
HKEX:1415
|
CN |
|
Heritage Foods Ltd
NSE:HERITGFOOD
|
IN |
Lipocine Inc
Total Receivables
Lipocine Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lipocine Inc
NASDAQ:LPCN
|
Total Receivables
$1.2m
|
CAGR 3-Years
144%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
24%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Receivables
$17.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Receivables
$14.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Receivables
$15.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Receivables
$12.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Receivables
$20.2B
|
CAGR 3-Years
33%
|
CAGR 5-Years
24%
|
CAGR 10-Years
17%
|
|
Lipocine Inc
Glance View
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. The company is headquartered in Salt Lake City, Utah and currently employs 13 full-time employees. The company went IPO on 2014-03-21. The firm is focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. The company has a portfolio of product candidates that target unmet needs for neurological and psychiatric central nervous system (CNS) disorders, liver diseases, and hormone supplementation for men and women. The firm's product candidate, TLANDO, is an oral testosterone replacement therapy (TRT) comprised of testosterone undecanoate (TU). Its additional pipeline candidates include LPCN 1148, LPCN 1144, LPCN 1111 (TLANDO XR), LPCN 1107, LPCN 1154 and LPCN 2101. Its LPCN 1144 is an oral prodrug of bioidentical testosterone comprised of TU for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) which has completed Phase II testing. Its TLANDO XR is an oral TRT product comprised of testosterone tridecanoate (TT), which has completed Phase II trials.
See Also
What is Lipocine Inc's Total Receivables?
Total Receivables
1.2m
USD
Based on the financial report for Dec 31, 2025, Lipocine Inc's Total Receivables amounts to 1.2m USD.
What is Lipocine Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
24%
Over the last year, the Total Receivables growth was 862%. The average annual Total Receivables growth rates for Lipocine Inc have been 144% over the past three years , and 24% over the past ten years .
